Study reveals metformin induces clinical remission and suppresses macrophage activation in NXG, indicating therapeutic potential.
Necrobiotic Xanthogranuloma (NXG) represents a rare granulomatous skin disease characterized by IFN-gamma-activated macrophages with limited treatment options. This study shows that metformin not only suppresses IFN-gamma-induced macrophage activation but also induces clinical remission in an NXG patient. These findings highlight metformin as a promising candidate for therapeutic repurposing in NXG.
No takes yet. Share an insight, caveat, or question.
Klapproth et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: